Moreover, while some studies have identified that subclonal nondriver mutations (i.e., ASXL1, EZH2, IDH1/2, and SRSF2) have an adverse effect on overall and leukemia-free survival [10, 11], and therefore may be used as a decisional tool for transplant (MIPPS70 [12]), this kind of analysis was not available in clinical practice in 2013, and the only information about the mutational status of our patient was the negativity for JAK2 V617F. This evidence concerns the gene JAK2 and leukemia.